Verrica Pharmaceuticals (NASDAQ:VRCA) Posts Earnings Results, Misses Expectations By $0.12 EPS

Verrica Pharmaceuticals (NASDAQ:VRCA) released its earnings results on Monday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12), Zacks reports. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The firm had revenue of ($1.78) million during the quarter, compared to the consensus estimate of $7.53 million.

Verrica Pharmaceuticals Stock Down 36.3 %

Shares of NASDAQ VRCA traded down $0.52 on Tuesday, reaching $0.91. 837,420 shares of the company’s stock traded hands, compared to its average volume of 435,121. The company has a quick ratio of 2.23, a current ratio of 2.36 and a debt-to-equity ratio of 29.58. The company has a market cap of $38.84 million, a price-to-earnings ratio of -0.49 and a beta of 1.45. The business’s 50 day simple moving average is $1.71 and its two-hundred day simple moving average is $5.21. Verrica Pharmaceuticals has a 12 month low of $0.75 and a 12 month high of $11.41.

Analyst Ratings Changes

VRCA has been the subject of several analyst reports. Needham & Company LLC restated a “hold” rating and set a $12.00 target price on shares of Verrica Pharmaceuticals in a report on Thursday, October 3rd. TD Cowen reduced their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, October 21st. Royal Bank of Canada cut Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Tuesday. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Verrica Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $11.40.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.